Literature DB >> 21826580

The challenge of imaging-guided therapeutic management.

Leslee J Shaw.   

Abstract

Mesh：

Year:  2011        PMID： 21826580     DOI： 10.1007/s12350-011-9440-6

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  8 in total

1.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Philip Greenland; Joseph S Alpert; George A Beller; Emelia J Benjamin; Matthew J Budoff; Zahi A Fayad; Elyse Foster; Mark A Hlatky; John McB Hodgson; Frederick G Kushner; Michael S Lauer; Leslee J Shaw; Sidney C Smith; Allen J Taylor; William S Weintraub; Nanette K Wenger; Alice K Jacobs; Sidney C Smith; Jeffrey L Anderson; Nancy Albert; Christopher E Buller; Mark A Creager; Steven M Ettinger; Robert A Guyton; Jonathan L Halperin; Judith S Hochman; Frederick G Kushner; Rick Nishimura; E Magnus Ohman; Richard L Page; William G Stevenson; Lynn G Tarkington; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2010-12-14       Impact factor: 24.094

2.  Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial.

Authors:  Yadon Arad; Louise A Spadaro; Marguerite Roth; David Newstein; Alan D Guerci
Journal:  J Am Coll Cardiol       Date:  2005-07-05       Impact factor: 24.094

Review 3.  27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management.

Authors:  R M Califf; P W Armstrong; J R Carver; R B D'Agostino; W E Strauss
Journal:  J Am Coll Cardiol       Date:  1996-04       Impact factor: 24.094

4.  Treatment of patients with intermediate cardiovascular risk: Are clinical measures enough?

Authors:  Alfred A Bove; William P Santamore; Carol Homko; Abul Kashem; Robert Cross; Timothy R McConnell; Gail Shirk; Francis Menapace
Journal:  J Nucl Cardiol       Date:  2011-08-02       Impact factor: 5.952

5.  Impact of coronary artery calcium scanning on coronary risk factors and downstream testing the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial.

Authors:  Alan Rozanski; Heidi Gransar; Leslee J Shaw; Johanna Kim; Lisa Miranda-Peats; Nathan D Wong; Jamal S Rana; Raza Orakzai; Sean W Hayes; John D Friedman; Louise E J Thomson; Donna Polk; James Min; Matthew J Budoff; Daniel S Berman
Journal:  J Am Coll Cardiol       Date:  2011-04-12       Impact factor: 24.094

6.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  N Engl J Med       Date:  2008-11-09       Impact factor: 91.245

7.  Community-based provision of statin and aspirin after the detection of coronary artery calcium within a community-based screening cohort.

Authors:  Allen J Taylor; Jody Bindeman; Irwin Feuerstein; Toan Le; Kelly Bauer; Carole Byrd; Holly Wu; Patrick G O'Malley
Journal:  J Am Coll Cardiol       Date:  2008-04-08       Impact factor: 24.094

Review 8.  Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging.

Authors:  Matthijs Oudkerk; Arthur E Stillman; Sandra S Halliburton; Willi A Kalender; Stefan Möhlenkamp; Cynthia H McCollough; Rozemarijn Vliegenthart; Leslee J Shaw; William Stanford; Allen J Taylor; Peter M A van Ooijen; Lewis Wexler; Paolo Raggi
Journal:  Int J Cardiovasc Imaging       Date:  2008-05-27       Impact factor: 2.357
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.